Literature DB >> 9740098

Validation of the three-dimensional acquisition mode in positron emission tomography for the quantitation of [18F]fluoro-DOPA uptake in the human striata.

R Trébossen1, B Bendriem, M J Ribeiro, A Fontaine, V Frouin, P Remy.   

Abstract

Three-dimensional (3D) positron emission tomography (PET) is attractive for [18F]fluoro-DOPA studies, since the sensitivity improvement is maximal for radioactive sources located in central planes, which is usually the case for the human striata. However, the image quantitation in that mode must be assessed because of the nearly threefold increase in scattered coincidences. We report the results of [18F]fluoro-DOPA studies performed on six normal volunteers. Each one was scanned in the 3D and two-dimensional (2D) modes on the same tomograph. The quantitation in the 3D and 2D modes was compared for a Patlak graphical analysis with the occipital counts as the input function (Ki) and a striatooccipital ratio analysis. We find that, in 3D PET, a scatter correction is required to preserve the same quantitation as in 2D PET. When the 3D data sets are corrected for scatter, the quantitation of the [18F]fluoro-DOPA uptake, using the Patlak analysis, is similar in the 2D and 3D acquisition modes. Conversely, analysis of the striatooccipital ratio leads to higher values in 3D PET because of a better in-plane resolution. Finally, using the 3D mode, the dose injected to the subjects can be reduced by a factor greater than 1.5 without any loss in accuracy compared to the 2D mode.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740098     DOI: 10.1097/00004647-199809000-00004

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  1 in total

1.  Direct comparison between 2-dimensional and 3-dimensional PET acquisition modes for myocardial blood flow absolute quantification with O-15 water and N-13 ammonia.

Authors:  Véronique Roelants; Anne Bol; Xavier Bernard; Ann Coppens; Jacques Melin; Bernhard Gerber; Jean-Louis Vanoverschelde
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.